此乃要件 請即處理 閣下如對本通函之任何內容或應採取之行動有任何疑問，應諮詢 閣下之股票經紀或其 他註冊證券交易商、銀行經理、律師、專業會計師或其他專業顧問。 閣下如已售出或轉讓名下所有遠大醫藥集團有限公司股份，應立即將本通函及隨附之代 表委任表格送交買主或承讓人，或經手買賣或轉讓之銀行、股票經紀或其他代理商，以 便轉交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不會就本通函全部或任何部分內容而 產生或因依賴該等內容而引致之任何損失承擔任何責任。 GRAND PHARMACEUTICAL GROUP LIMITED 遠 大 醫 藥 集 團 有 限 公 司* （ 於 百 慕 達 註 冊 成 立 之 有 限 公 司 ） （股份代號：00512） (1) 購回股份及發行新股份之一般授權； (2) 重選退任董事； 及 (3) 股東週年大會通告 遠大醫藥集團有限公司謹訂於二零二五年四月十日（星期四）上午十一時正假座香港皇后 大道中99號中環中心3302室舉行股東週年大會或其任何續會，股東週年大會通告載於本 通函第13至17頁。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不就因本通告全部或任何部分內容而 產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （ 於 百 慕 達 註 冊 成 立 之 有 限 公 司 ） （股份代號：00512） 股東週年大會通告 茲通告遠大醫藥集團有限公司（「本公司」）謹訂於二零二五年四月十日（星期四）上午十一 時正假座香港皇后大道中99號中環中心3302室舉行股東週年大會（「股東週年大會」），以 便處理下列事項： — 1 — 1. 採納截至二零二四年十二月三十一日止年度之經審核財務報表及董事會報告書與核 數師報告書。 2. 宣派截至二零二四年十二月三十一日止年度末期股息每股港幣0.26元。 3. (a) 重選楊光先生為本公司執行董事； (b) 重選林芷伊女士為本公司執行董事； (c) 重選邢麗娜博士為本公司獨立非執行董事；及 (d) 授權董事會釐定本公司董事之酬金。 4. 重聘國衛會計師事務所有限公司為核數師，任期直至下屆股東週年大會結束為止， 並授權董事會釐定其酬金。 作為特別事項，考慮及酌情通過下列決議案為普通決議案（不論 ...

主席致辭 03 | 01 築基 | | | --- | --- | | 責任引領，行穩致遠 | | | 完善企業管治 | 12 | | 強化 ESG 治理 | 13 | | 利益相關方參與 | 15 | | 重大性議題矩陣 | 17 | | 商業道德 | 19 | | 風險管理 | 23 | | 信息安全及隱私保護 | 27 | 目錄 環境、社會及管治報告 關於本報告 02 | 03 堅守 | | | --- | --- | | 質量至上，守護健康 | | | 質量管理 | 44 | | 臨床倫理 | 50 | | 藥物警戒 | 52 | | 責任營銷 | 55 | | 04 | | --- | | 惜才 | | 攜手員工，共赴成長 | 06 共繪 同舟共濟，共築美好 | 供應鏈管理與發展 | 94 | | --- | --- | | 行業共建 | 100 | | 回饋社會 | 102 | 05 健康環境，綠色共榮 76 84 87 89 | 104 | 附錄一： | | --- | --- | | | 關鍵績效表 | 58 62 67 71 人才多元與包容 人才培訓與發展 人才保留與關愛 職業健康與安全 0 ...

Industry Growth and Market Potential - In 2024, China's pharmaceutical manufacturing industry saw a year-on-year growth of 3.6% in industrial added value above designated size, although this was lower than the overall industrial growth rate[6]. - The Chinese market for radiopharmaceuticals is projected to reach RMB 9.3 billion by 2025, with a compound annual growth rate (CAGR) of 22.7% from 2025 to 2030[9]. - The innovative ophthalmic drug market in China is expected to grow to RMB 44 billion by 2025 and RMB 116.6 billion by 2030, with a CAGR of approximately 19.8%[11]. - The pharmaceutical industry in China is expected to experience strong growth driven by policy reforms and globalization, with increased demand for innovative drugs[13]. Strategic Acquisitions and Partnerships - The company successfully completed strategic acquisitions, including 100% stakes in Tianjin Tanabe Pharmaceutical Co., Nanchang Baiji Pharmaceutical Co., and Jiangxi Bai'an Baiyu Pharmaceutical Technology Co., significantly expanding its presence in cardiovascular and respiratory fields[8]. - The group acquired 100% of Tianjin Tanabe for approximately RMB 486 million, entering the chronic disease market and expanding its cardiovascular product portfolio[31]. - The group purchased 100% of Baiji Pharmaceutical for about RMB 260 million, becoming one of the companies with the most comprehensive product pipeline for allergic rhinitis in China[31]. - The company has established strategic partnerships and collaborations, including with Telix Pharmaceutical Limited, enhancing its product pipeline in the nuclear medicine field[9]. - A strategic cooperation agreement has been reached with Jixing Pharmaceutical Hong Kong Co., Ltd. for the exclusive development and commercialization rights of the innovative nasal spray products OC-01 and OC-02 in the Greater China region[28]. Research and Development Initiatives - The company has 147 ongoing research and development projects with an investment of approximately HKD 2.27 billion[21]. - 63 significant milestones were achieved in the R&D efforts during the year[21]. - The R&D portfolio consists of 47 innovative projects, accounting for 32% of the total, and 100 generic and other projects, making up 68%[23]. - The company is focusing on innovation in nuclear medicine, respiratory and critical care, ophthalmology, and cardiovascular precision intervention[15]. - The company plans to enhance its R&D capabilities through collaboration with leading medical institutions domestically and internationally[15]. Financial Performance - The company's revenue for the year ended December 31, 2024, reached HKD 11,644,892, representing a 10.6% increase from HKD 10,529,590 in 2023[40]. - The profit before tax for 2024 was HKD 2,852,363, up from HKD 2,344,197 in 2023, indicating a growth of 21.7%[40]. - Net profit attributable to shareholders for 2024 was HKD 2,466,059, a 30% increase compared to HKD 1,895,442 in 2023[40]. - Total assets as of December 31, 2024, amounted to HKD 24,991,165, an increase from HKD 22,515,326 in 2023, reflecting a growth of 11.0%[42]. - The company achieved a compound annual growth rate (CAGR) of 12% in revenue from 2020 to 2024[45]. Product Development and Innovations - The company introduced innovative products, including a unique eye formulation for treating Demodex blepharitis and a new mechanism nasal spray for treating dry eye syndrome, enhancing its portfolio in the ophthalmology sector[8]. - The innovative product STC3141 for severe diseases has successfully completed all patient enrollments in Phase II clinical trials in China[12]. - The global innovative ophthalmic drug GPN01768 (TP-03, Loteprednol Etabonate eye drops, 0.25%) has submitted a New Drug Application (NDA) to the regulatory authority and received acceptance[28]. - The innovative drug GPN00833 for postoperative inflammation and pain has received FDA approval in March 2024 and has shown significant statistical differences in anti-inflammatory and analgesic effects compared to the control group in clinical trials[116]. - The company has launched 14 new commercialized products in 2024, including innovative products in oncology and cardiovascular intervention sectors[49]. Market Expansion and Globalization - The international sales network covers over 140 countries and regions, with overseas business accounting for more than 40% of total sales[141]. - The company is expanding its R&D capabilities with multiple platforms globally, including a focus on mRNA technology for anti-tumor and anti-infection drugs[156]. - The company has accelerated its globalization efforts, with over 320 employees overseas and 8 clinical approvals in the US, Australia, Belgium, Poland, and the UK[164]. Regulatory Approvals and Clinical Trials - The global innovative RDC drug ITM-11 for treating gastroenteropancreatic neuroendocrine tumors has received formal approval for a Phase III clinical study (COMPETE bridging trial) in China[27]. - The global innovative temperature-sensitive embolic agent GPN00289 has completed the first patient enrollment in a registration clinical study for primary liver cancer transarterial chemoembolization in China[28]. - The NDA application for the global innovative drug Ryaltris® nasal spray for allergic rhinitis has been accepted by the drug regulatory authority[31]. - The company has submitted Investigational New Drug (IND) applications for two Phase III clinical trials for ITM-11, targeting gastroenteropancreatic neuroendocrine tumors (GEP-NETs), which have been approved by the regulatory authority[51]. Corporate Governance and Sustainability - The company is actively pursuing ESG initiatives, promoting green pharmaceutical practices and enhancing access to quality medical resources[12]. - The group is committed to environmental sustainability through initiatives like water conservation and recycling[187]. - The group has established long-term relationships with suppliers, ensuring compliance with quality and ethical standards[190]. Challenges and Legal Matters - The company has been involved in several lawsuits related to product quality issues, with a total compensation of approximately RMB 40,199,645.99 paid as a result of 75 court judgments as of December 31, 2024[171]. - The company has successfully recovered RMB 10,000,000 from a previous equity transfer agreement and is pursuing an additional RMB 11,228,044.48 from the seller due to unmet performance commitments[172].

(Incorporated in Bermuda with limited liability) ( 於百慕達註冊成立之有限公司 ) (Stock Code 股份代號: 00512) 各位非登記股東： 遠大醫藥集團有限公司*（「本公司」）- 可供查閱通知 - 年度報告及通函（「本次公司通訊」）的刊發通知 本公司的本次公司通訊備有中、英文版本，並已上載於本公司網站 www.grandpharma.com 及香港交易所披露易（「披露易」）網站 www.hkexnews.hk，歡迎瀏覽。 若 閣下已選擇收取本公司的公司通訊（「公司通訊」） （附註） 之印刷本，則隨函附奉 閣下所選擇之本次公司通訊印刷本。 閣下若因任何 理由以致在收取或接收載於本公司網站上的本次公司通訊出現困難，本公司將於接到 閣下通知後，盡快向 閣下免費發送有關本次 公司通訊的印刷本； 閣下可以書面方式通知本公司的香港股份過戶登記處（「股份過戶處」）香港中央證券登記有限公司，地址為香 港灣仔皇后大道東 183 號合和中心 17M 樓，或電郵至 grandpharma.ecom@computershare.com.hk。 閣下有權要求更改所選擇收取日 ...

閣下有權要求更改所選擇收取日後公司通訊的收取方式，請填妥隨附之回條（「回條」），然後以專人交付或使用回條底部隨附的郵 寄標籤將回條寄回股份過戶處（如在香港投寄，毋須貼上郵票；否則，請貼上適當的郵票）； 閣下亦可把已填妥及簽署回條的掃描 副本以電郵方式發送至 grandpharma.ecom@computershare.com.hk。 以電子方式發布公司通訊之安排 根據自 2023 年 12 月 31 日起生效的擴大無紙化制度及以電子方式發布公司通訊規定下香港聯合交易所有限公司證券上市規則（「上市 規則」）第 2.07 條，本公司*謹此通知 閣下，本公司已採用以電子方式發布公司通訊之安排。請注意，所有未來公司通訊的英文版和 中文版將在公司網站 www.grandpharm.com 和披露易網站 www.hkexnews.hk 上提供，以代替印刷本。 徵集電子聯絡資料 為確保及時收到最新的公司通訊，本公司建議 閣下透過掃描隨附之回條上列印的 閣下專屬二維碼來提供 閣下的電子郵件地址。 或者， 閣下也可以簽署回條並交回股份過戶處。 如果本公司沒有收到 閣下的有效電子郵件地址，直至股份過戶處收到 閣下有效的電子郵件地 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而 產生或因倚賴該等內容而引致的任何損失承擔任何責任。 承董事會命 遠大醫藥集團有限公司 主席 唐緯坤博士 香港，二零二五年三月十八日 Grand Pharmaceutical Group Limited 遠大醫藥集團有限公司* ( 於百慕達註冊成立之有限公司 ) (股份代號: 00512) 澄清公告 公司細則 茲提述遠大醫藥集團有限公司（「本公司」）於二零二三年六月二日在週年大會上通過 特別議程，在「展示文件」下刊發的公司細則。 本公司謹此澄清因操作錯誤，該文件的標題誤選為「展示文件」，正確標題為 「憲章文 件」。 公司細則內容並無錯誤，並已於二零二五年三月十八日以正確標題重新上傳。 於本公告日期，董事會由四名執行董事唐緯坤博士、周超先生、楊光先生及林芷伊女士，及四 名獨立非執行董事蘇彩雲女士、邢麗娜博士、裴更博士及胡野碧先生組成 。 * 僅供識別 -1- ...

另外，公司去年呼吸及危重症板块录得收入约17.1亿港元，同比增长约26.9%。 收入盈利双增下，公司拟分红总计约9.1亿港元。 业务方面，公司去年核药板块实现收入近5.9亿港元，同比增长近177%。 人民财讯3月13日电，3月12日晚间，远大医药公布了2024年度业绩：公司全年实现收入约116.4亿港 元，剔除汇率影响同比增长约12.8%；归母净利润约24.7亿港元，剔除汇率影响同比增长约34.0%。 ...

EF001 其他信息 其他信息 不適用 發行人董事 董事會由四名執行董事唐緯坤博士、周超先生、楊光先生及林芷伊女士；及四名獨立非執行董事蘇彩雲女士、邢麗娜博士、胡野碧 先生及裴更博士組成。 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | 股票發行人現金股息公告 | | | 發行人名稱 | 遠大醫藥集團有限公司 | | 股份代號 | 00512 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至二零二四年十二月三十一日止年度之末期股息 | | 公告日期 | 2025年3月12日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2024年12月31日 | | 宣派股息的報告期末 | 2024年12月31日 | | 宣派股息 | 每 股 0.26 HKD | | ...

Financial Performance - For the year ending December 31, 2024, the company's revenue was approximately HKD 11,644,890,000, representing a year-on-year growth of about 10.6%[3] - The profit attributable to shareholders for the same period was approximately HKD 2,468,380,000, an increase of about 31.3% compared to the previous year[3] - The distribution costs and administrative expenses for the year were approximately HKD 3,256,890,000 and HKD 1,365,370,000, respectively, reflecting increases of about HKD 689,260,000 and HKD 130,990,000 compared to the previous year[150] - The pharmaceutical technology products recorded revenue of approximately HKD 7,317,840,000, which is a year-on-year increase of about 9.6%[148] - The biotechnology products generated revenue of approximately HKD 3,510,840,000, marking a year-on-year increase of about 5.9%[149] Research and Development - The company invested approximately HKD 2,273,960,000 in research and development, including capitalized R&D expenses and prepayments for new projects[3] - The company has a total of 147 projects in the research pipeline, with 47 innovative projects at various stages from preclinical to new drug application[160] - The R&D team consists of over 770 personnel, with more than 525 holding master's or doctoral degrees, representing approximately 68% of the team[164] - The group applied for 98 new patents during the reporting period, with 78 being invention patents, accounting for 80% of the total[168] - The group has a total of 741 valid patents, including 453 invention patents, emphasizing the importance of intellectual property protection in innovation[168] Product Development and Innovation - The company launched 14 new commercialized products this year, including 1 new nuclear medicine product for early detection of urinary tract cancer and 5 cardiovascular intervention products[23] - The innovative drug CBT-001 for treating pterygium has completed patient enrollment in its Phase III clinical study in China[12] - The innovative product Yigan Tai® Yttrium-90 microsphere injection has been used by over 150,000 patients across more than 50 countries, and is recommended by multiple international clinical guidelines[45] - The company is focusing on expanding its product pipeline in the fields of ophthalmology and respiratory diseases, with multiple innovative products reaching significant R&D milestones[18] - The company is advancing its innovative pipeline with a well-structured layout, creating a strong ladder effect in drug development[160] Strategic Acquisitions and Partnerships - The company completed strategic acquisitions, including a controlling stake in DPT Pharmaceuticals and 100% ownership of Tianjin Tanabe Pharmaceutical and Nanchang Baiji Pharmaceutical[8] - The company has established strategic partnerships with several biotech firms to expand its innovative ophthalmic product pipeline, including the preservative-free nasal spray OC-01[12] - The group acquired 100% equity of Baiji Pharmaceutical for approximately RMB 260 million, gaining access to advanced nasal spray technology[175] - The group agreed to acquire 100% equity of Tianjin Tanabe for approximately RMB 486 million, enhancing its capabilities in the cardiovascular emergency sector[177] - A strategic cooperation agreement was reached to introduce a global innovative eye treatment product for meibomian gland dysfunction, with an upfront payment of $15 million[174] Market Trends and Projections - The nuclear medicine sector is projected to grow significantly, with the market size expected to reach RMB 9.3 billion by 2025, and a compound annual growth rate of 22.7% from 2025 to 2030[9] - The Chinese ophthalmic drug market is projected to reach RMB 44 billion by 2025 and RMB 116.6 billion by 2030, with a compound annual growth rate of approximately 19.8%[14] - The pharmaceutical industry in China is expected to experience significant growth driven by policy reforms and globalization, with a focus on innovation and regulatory efficiency[16] - The company is committed to expanding its capabilities in rare diseases and protein replacement therapies through its mRNA technology platform[163] - The group plans to focus on high-end parenteral nutrition formulations, innovative peptide drugs, and other high-value areas in the health consumption sector, indicating strong future growth potential[143] Corporate Social Responsibility and Governance - The company is committed to ESG principles, promoting green pharmaceutical practices and enhancing access to quality medical resources[15] - The group has been recognized with multiple awards for investor relations, including the "Best Investor Relations Company Award" in the pharmaceutical and healthcare sector in February 2024[181] - The group is actively pursuing litigation related to product quality incidents, with compensation payments totaling approximately RMB 40,199,645.99 made as a result of 75 court judgments[183] - The group plans to utilize its operating income, internal resources, and bank credit for its operational and investment activities, indicating a stable financial position[190] - The group has established a share incentive plan, with approximately HKD 278,560,000 allocated to the trust, resulting in the purchase of 47,761,500 shares, representing about 1.35% of the company's issued shares[197]